Donidalorsen Sodium 80 mg/0.8 mL Suppliers & Bulk Manufacturers
Available Forms: Injection (Autoinjector)
Available Strengths: 80 mg/0.8 mL
Originator reference: Dawnzera (USA) (brand names belong to their owners and are shown only to identify the originator medicine)
Category: Immune Disorder
Donidalorsen is an RNA-targeted antisense oligonucleotide medication used to prevent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. It works by reducing production of plasma prekallikrein (PKK), a key protein in the pathway that triggers swelling episodes. Administered via subcutaneous injection every 4 or 8 weeks, Dawnzera significantly lowers the frequency of HAE attacks.
Manufacture or export Donidalorsen Sodium? List it or send an offer →
Product Description:
Donidalorsen is an antisense oligonucleotide that targets the messenger RNA for prekallikrein in liver cells, reducing how much of that protein is made. Prekallikrein is the precursor of plasma kallikrein, the enzyme that generates bradykinin — the mediator responsible for the swelling attacks of hereditary angioedema. Lowering the precursor lowers the whole downstream cascade.
It is used to prevent attacks in hereditary angioedema in patients aged twelve and over, given as a subcutaneous injection every four or eight weeks depending on response. In trials it reduced monthly attack rates by around ninety percent, with many patients becoming attack-free. It is a preventive: patients still need an on-demand treatment for breakthrough attacks. Injection site reactions are the commonest adverse effect. Because the mechanism reduces a specific liver protein rather than suppressing immunity broadly, infection risk is not a feature of its profile.
Sourcing notes. Originator product approved in 2025, on patent, no generic. Supplied in an autoinjector for home use after training. Cold chain, with a defined room-temperature period. It competes with an anti-kallikrein antibody and an anti-factor XIIa antibody in the same prophylaxis market, so the argument is dosing interval and route rather than mechanism alone.
How Donidalorsen Sodium is supplied today, and licensing ahead of patent expiry
Where donidalorsen is approved
Checked 3 Oct 2026| Market | Status | Brand · regulator · date |
|---|---|---|
| United States | Approved | Dawnzera · FDA · Aug 2025 |
| European Union | Approved | Dawnzera · European Commission · Jan 2026 |
| Generic / biosimilar | None | None approved as of the check date |
Not approved in your country? A hospital or doctor can often still import it for a named patient, through a special-access, import-permit or compassionate-use route. We confirm which route applies in your country and the documents needed before quoting. Ask about named-patient supply →
Frequently Asked Questions
Dawnzera (Donidalorsen) is developed and sold by Ionis (Otsuka outside the US). PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.
Related Products
Reslizumab
Strength:
10mg/ml
Form: Injection
Originator reference: CINQAIR (USA), CINQAERO (EU)
View DetailsCertolizumab Pegol
Strength:
200mg
Form: injection (prefilled syringe)
Originator reference: Cimzia (USA/EU)
View DetailsAbrocitinib
Strength:
50 mg, 100 mg, 200 mg
Form: Tablets
Originator reference: Cibinqo (USA/EU)
View DetailsDeflazacort 6 mg Tablet
Strength:
6 mg, 18 mg
Form: Tablets
Originator reference: Emflaza (USA), Calcort (EU)
View DetailsPrednisone 5 mg Tablet
Strength:
1 mg, 2.5 mg, 5 mg, 5 mg/5 mL
Form: Tablets / Oral solution
Originator reference: Deltasone (USA)
View DetailsGolimumab
Strength:
50 mg / 0.5 mL, 100 mg / 1 mL
Form: injection (prefilled syringe)
Originator reference: Simponi (USA/EU)
View DetailsDupilumab
Strength:
200 mg/1.14 mL, 300 mg/2 mL
Form: injection (prefilled syringe/ Prefilled Pen)
Originator reference: Dupixent (USA)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit